A New Drug May Silence a Cruel Side Effect of Chemotherapy

TÜBINGEN, Germany – June 12, 2026 – For hundreds of thousands of cancer patients each year, the relief of life-saving chemotherapy is often shadowed by a devastating trade-off: permanent, irreversible hearing loss. This cruel bargain is a well-known reality for those treated with cisplatin, a potent and widely used anti-cancer drug. But now, a German biotechnology firm has offered a significant glimmer of hope, announcing promising results for a drug designed to protect the delicate structures of the inner ear without interfering with the fight against cancer.

Acousia Therapeutics GmbH today revealed positive top-line data from its Phase 2a clinical trial, PROHEAR. The study investigated a first-in-class drug, ACOU085 (Bimokalner), in young testicular cancer patients, a group for whom cisplatin is a cornerstone of a cure. The results suggest the drug provided a clinically meaningful level of protection against hearing damage, a milestone that could represent a paradigm shift in supportive care for oncology patients.

The Silent Toll of a Lifesaving Drug

Cisplatin is a workhorse in oncology, effective against a range of solid tumors. Its discovery transformed prognoses, particularly for testicular cancer, turning a once-fatal disease into one with a high cure rate. But this efficacy comes at a cost. The drug is notoriously ototoxic, meaning it is poisonous to the ear. Up to 80% of patients treated with cisplatin experience some degree of hearing loss, a condition known as cisplatin-induced hearing loss (CIHL).

The damage is permanent. Cisplatin attacks the cochlea's outer hair cells (OHCs), the microscopic sensory cells that act as the ear's biological amplifiers, allowing us to perceive quiet sounds and distinguish between frequencies with precision. Once these cells are destroyed, they do not regenerate. The loss typically begins in the high frequencies—the subtle sounds that provide clarity to speech—and can progress, leading to social isolation, developmental delays in children, and a significant decline in quality of life. The PROHEAR study itself underscored the severity of the problem: over 90% of its young, hearing-healthy participants developed ototoxicity in at least one ear after just three chemotherapy cycles.

Until now, the options for preventing this have been starkly limited. While one drug, sodium thiosulfate, is approved for pediatric patients, there is no approved preventative therapy for the vast majority of adult patients. This leaves clinicians and patients confronting an agonizing choice between aggressive, curative treatment and the long-term integrity of one of their most vital senses.

A New Mechanism of Defense

ACOU085 represents a fundamentally new strategy. Rather than attempting to mop up toxins systemically, which risks neutralizing the chemotherapy itself, Acousia's drug works locally to bolster the ear's own defenses. The treatment is administered via a transtympanic injection—a procedure that delivers a proprietary slow-release gel formulation directly into the middle ear, allowing the drug to diffuse into the cochlea where it is needed most.

The drug's target is a specific protein called the Kv7.4 potassium channel. These channels are critical gatekeepers in the outer hair cells, helping to maintain their electrochemical stability and protect them from stress. By acting as an 'agonist,' ACOU085 essentially props open these channels, enhancing the hair cells' natural resilience against the toxic onslaught of cisplatin. Preclinical studies had already shown this approach could preserve the delicate hair cell structures, but the PROHEAR results provide the first clinical evidence in humans.

“This is an important and encouraging milestone toward establishing Kv7.4 activation as a novel therapeutic approach for multiple forms of hearing loss,” said Professor Hubert Löwenheim, the study's Scientific Supervisor and a foundational figure in the company's creation. He noted that the drug's potential addresses a significant unmet need that “current device-based solutions only partially meet.”

A Clever Trial and a Clear Signal

The design of the PROHEAR study was particularly elegant. Using a 'split-body' protocol, each of the 40 male patients served as their own control. One ear received the ACOU085 injection, while the other received a placebo. This intra-patient comparison is a powerful method for filtering out individual variability and getting a clear signal of a drug's effect. The results, according to the company, showed a clinically meaningful prevention of hearing threshold increases in the ears treated with ACOU085 compared to those that received the placebo.

“Today represents an exciting advancement for cancer patients at risk of cisplatin-induced hearing loss,” said Tim Boelke, M.D., CEO & CMO of Acousia Therapeutics. “Our novel drug candidate has the potential to prevent permanent inner ear damage commonly seen after cisplatin-based chemotherapy.”

The company plans to submit the full data for publication in a peer-reviewed journal, which will provide the scientific community with a more granular look at the safety and efficacy profile. In the meantime, the top-line results are a powerful validation for the small clinical-stage company.

The Road Ahead

For Acousia, these results are a pivotal moment, transforming a scientific hypothesis into a viable clinical asset. The next steps are crucial. The company will be attending the BIO International Convention in San Diego later this month, a key venue for biotech firms to forge the strategic partnerships necessary to fund and execute larger, more definitive Phase 3 trials—the final step before seeking regulatory approval.

The potential market is substantial. Over 500,000 patients worldwide receive cisplatin annually. A successful otoprotective agent would not only improve the lives of countless cancer survivors but also create a new multi-billion dollar market in pharmacological hearing preservation, shifting the focus from hearing aids to biological intervention.

The successful validation of the Kv7.4 channel as a therapeutic target may also have implications far beyond oncology, potentially opening doors for treating other forms of hearing loss, including age-related decline. While the road to regulatory approval is long and fraught with challenges, these results mark a critical step forward, offering the promise that in the future, the sound of a cancer cure may no longer be silence.